Language

CAS NO:1232416-25-9 Berzosertib(VE-822)

CAS NO:1232416-25-9 NAME:Berzosertib(VE-822) Other name:5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine MF：C24H25N5O3S MW：463.55 EINECS NO：1592732-453-0 Purity:95%+ COA:Light Yellow solid

Categories：

Life Science Chemicals

Pharmaceutical Intermediates

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

PRODUCT NAME	Berzosertib(VE-822)
CAS NO	1232416-25-9
MP	>197°C (dec.)
BP	674.4±55.0 °C(Predicted)
DENSITY	1.263±0.06 g/cm3(Predicted)
STORAGE	2-8°C
DELIVERY	2-3DAYS
PACKAGE	According client's request

Description of CAS NO:1232416-25-9 Berzosertib(VE-822)

VE 822 CAS NO:1232416-25-9 is a novel drug that has been shown to be effective against squamous carcinoma in vitro. VE 822 binds to the polymerase chain and inhibits its synthesis of RNA, halting cell growth and preventing the duplication of genetic information. This drug also has minimal toxicity in laboratory mice with solid tumours and does not show any signs of drug interactions. VE 822 may be able to inhibit radiation-induced tumorigenesis by preventing the formation of reactive oxygen species (ROS).

Berzosertib (VE-822, VX-970, M6620) is a drug originally invented by Vertex Pharmaceuticals and licensed to Merck KGaA, Darmstadt, Germany, for development . It acts as a potent inhibitor of the enzyme ataxia telangiectasia and Rad3 related (ATR) and with lower potency as an inhibitor of ATM serine/threonine kinase (ATM) . These enzymes are both involved in detecting DNA damage as part of cell cycle checkpoints during cell division.

Applications of CAS NO:1232416-25-9 Berzosertib(VE-822)

1.Cancer Treatment
Berzosertib is being developed in combination with chemotherapy for the treatment of patients with advanced cancers . It is a selective and potent inhibitor of ataxia–telangiectasia and Rad3-related (ATR) for intravenous administration . The rationale for clinical development is based on the observation that DNA damaging drugs and ionizing radiation are widely used as standard of care for the treatment of many solid tumors.

2.Gastric Cancer
Berzosertib has been found to inhibit gastric cancer cell proliferation via the base excision repair system . The prognostic value of BER system members in gastric cancer remains unclear

3.Small Cell Lung Cancer (SCLC)

4.COVID-19 Treatment

5.Combination Therapies
Berzosertib has been used in combination with other compounds such as Lurbinectedin and Gemcitabine in experimental settings . These combinations have shown potential in inducing cell mutations and improving progression-free survival (PFS) in platinum-resistant ovarian cancer

Key words: